Medicine Grand Rounds– The 2024 Neff Distinguished Lectureship - STRUCTURE MATTERS: Cancer Health Disparities
Presented by Robert A. Winn, MD, Director and Lipman Chair in Oncology, VCU Massey Cancer Center, Senior Associate Dean for Cancer Innovation and Professor of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University School of Medicine

Join us in person! Bruce Schroffel Auditorium, University of Colorado Hospital, Anschutz Inpatient Pavilion 2, First Floor Conference Room – Lunch Provided
or via Zoom.

Learning Objectives:

• Aims to build awareness and advance understanding about the impact systemic health inequities have on cancer early detection and treatment
• How trust can be established between patients and caregivers.
• Exploring the importance of efforts to increase the diversity of participants in clinical trials

Accreditation & Designation Statement: The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement: Dr. Robert Winn reports a financial relationship as a Consultant for Genentech, Phillips, and Merck. All of the relevant financial relationships listed for this individual have been mitigated. All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.